Clinical Trials Browser

Phase NA × Refractory Solid Tumors × Clear all

NCT02450123 2022-06-15

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Phase NA Completed

Other solid neoplasm

Refractory Solid Tumors

NCT02450136 2022-06-15

Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors

Phase NA Completed

Other solid neoplasm

Refractory Solid Tumors

NCT02691767 2022-06-15

Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors

Phase NA Completed

Other solid neoplasm

Refractory Solid Tumors

NCT02691780 2019-12-30

Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors

Phase NA Withdrawn

Other solid neoplasm

Refractory Solid Tumors

NCT02450149 2017-03-13

Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors

Phase NA Completed

Other solid neoplasm

Refractory Solid Tumors